Turkmenistan

Reimbursed Care Access

Turkmenistan maintains a highly restrictive national drug-control regime: classical/serotonergic psychedelics (psilocybin, MDMA, DMT, 5‑MeO‑DMT, mescaline, 2C‑X), ceremonial/exotic botanicals (ayahuasca, ibogaine) and designer phenethylamines are effectively prohibited for general use and only accessible within tightly controlled research or by exception — there is no public, reimbursed medical psychedelics program. Ketamine is used in clinical practice as an anaesthetic and is included on global essential‑medicine lists, but there is no evidence of an established, reimbursed program for esketamine (Spravato) or psychedelic-assisted psychiatric treatments in Turkmenistan. Trade and import of narcotics and psychotropic substances are under strict presidential/cabinet licensing controls. [https://www.trade.gov/country-commercial-guides/turkmenistan-prohibited-and-restricted-imports|U.S. Dept. of Commerce - Turkmenistan Prohibited & Restricted Imports]; the main internationally controlled classical psychedelics (psilocybin, MDMA, DMT, mescaline, ibogaine, etc.) are listed under UN/INCB scheduling frameworks that countries commonly enforce domestically. [https://www.incb.org/incb/en/psychotropic_substances/psychotropic_index.html|INCB - Psychotropic Substances Index]